Generic Medicine Info
Prolonged release tab: May be taken with or without food. Swallow whole, do not chew/crush.
Orodispersible extended release tab: Should be taken with food. Place on the tongue & allow to dissolve. Then, swallow w/ saliva or water.
Cap: Should be taken with food. Take 30 min following the same meal daily. Swallow whole, do not open/chew/crush.
History of orthostatic hypotension. Severe renal impairment CrCl <10 mL/min. Severe hepatic impairment (Child-Pugh scores >9). Concomitant use with strong CYP3A4 inhibitors in CYP2D6 poor metabolisers.
Special Precautions
Patient with myocardial dysfunction or angina pectoris; history of sulphonamide allergy; prostate cancer. Discontinue therapy 5-9 weeks prior to cataract or glaucoma surgery. Not indicated for use in women. Patient Counselling This medicine may cause dizziness and syncope, if affected, do not drive or operate machinery. Monitoring Parameters Rule out prostate carcinoma with screening prior to initiation of therapy and screen at regular intervals. Monitor blood pressure and urinary symptoms. Perform digital rectal examination prior to treatment then regularly, thereafter.
Adverse Reactions
Significant: 1st dose orthostatic hypotension, syncope, floppy iris syndrome in cataract and glaucoma surgery, hypersensitivity reactions, MI exacerbations. Cardiac disorders: Dyspnoea, palpitations. Eye disorders: Visual impairment, blurred vision. Gastrointestinal disorders: Constipation, vomiting, dry mouth, diarrhoea, nausea. General disorders and administration site conditions: Malaise. Nervous system disorders: Headache, dizziness. Reproductive system and breast disorders: Ejaculation disorders including retrograde ejaculation, ejaculation failure, rarely, priapism. Respiratory, thoracic and mediastinal disorders: Rhinitis. Skin and subcutaneous tissue disorders: Pruritus, urticaria, skin desquamation including erythema multiforme, dermatitis exfoliative, rarely, Stevens-Johnson syndrome. Vascular disorders: Hypotension, epistaxis.
Drug Interactions
Increased serum concentration with weak or strong CYP3A4 inhibitors (e.g. cimetidine, ketoconazole) and strong CYP2D6 inhibitors (e.g. paroxetine). Decreased plasma levels with furosemide. Increased elimination rate with diclofenac and warfarin. Enhanced hypotensive effect with PDE5 inhibitors. May enhance the antihypertensive effect of other α1-adrenoceptor blockers.
CIMS Class
Drugs for Bladder & Prostate Disorders
ATC Classification
G04CA02 - tamsulosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Disclaimer: This information is independently developed by CIMS based on tamsulosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in